Chronic lymphocytic leukemia (CLL) accounts for approximately 25–30% of all leukemias occurring in the Western hemisphere. It is a disease characterized by marked heterogeneity in clinical behavior ...

Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia ...

B-cell chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in Western countries. It accounts for 95% of chronic leukemia cases and 25% of all leukemia. Despite the prevalence of ...

Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer We calculated smudge cell percentages (ratio of ...

Please provide your email address to receive an email when new articles are posted on . However, the bendamustine (Treanda, Teva) and rituximab (Rituxan; Genentech, Biogen) combination is associated ...

Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the ...

Lymphocytosis and smudge cells are characteristic signs of chronic lymphocytic leukemia. They can also be signs of conditions such as other cancers, infections, and autoimmune diseases. Lymphocytosis ...